{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:02:18Z","timestamp":1791234138019,"version":"4.1.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA204-013"],"award-info":[{"award-number":["CA204-013"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA-204-156"],"award-info":[{"award-number":["CA-204-156"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["CA-204-214"],"award-info":[{"award-number":["CA-204-214"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA-06927"],"award-info":[{"award-number":["CA-06927"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02551","type":"journal-article","created":{"date-parts":[[2018,11,4]],"date-time":"2018-11-04T23:32:01Z","timestamp":1541374321000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":116,"title":["Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma"],"prefix":"10.3389","volume":"9","author":[{"given":"Kerry S.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Pazina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fimmu.2013.00481","article-title":"Combination immune therapies to enhance anti-tumor responses by NK cells","volume":"4","author":"Mentlik","year":"2013","journal-title":"Front Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1053\/j.seminoncol.2018.01.002","article-title":"Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma","volume":"44","author":"Vandross","year":"2017","journal-title":"Semin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.15116","article-title":"Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma","volume":"181","author":"Varga","year":"2018","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-16-0184","article-title":"New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma","volume":"22","author":"Neri","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van","year":"2018","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3389\/fimmu.2018.01228","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"9","author":"Plesner","year":"2018","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.4049\/jimmunol.180.9.6392","article-title":"Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy","volume":"180","author":"Binyamin","year":"2008","journal-title":"J Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","journal-title":"Cancer Biol Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","article-title":"Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma","volume":"129","author":"Kroger","year":"2005","journal-title":"Br J Haematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood-2010-03-273706","article-title":"Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma","volume":"116","author":"Gabriel","year":"2010","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.humimm.2009.07.004","article-title":"Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells","volume":"70","author":"Bernal","year":"2009","journal-title":"Hum Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1 \/ PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell Mol Life Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 blockade enhances elotuzumab efficacy in mouse tumor models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3389\/fimmu.2017.01444","article-title":"Restoring natural killer cell immunity against multiple myeloma in the era of new drugs","volume":"8","author":"Pittari","year":"2017","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2007-03-078535","article-title":"Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma","volume":"111","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.4049\/jimmunol.0901797","article-title":"Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation","volume":"183","author":"Fionda","year":"2009","journal-title":"J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"23609","DOI":"10.18632\/oncotarget.4603","article-title":"The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma","volume":"6","author":"Fionda","year":"2015","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1218105","DOI":"10.1080\/2162402X.2016.1218105","article-title":"Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells","volume":"5","author":"Antonangeli","year":"2016","journal-title":"Oncoimmunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.CIR-17-0604","article-title":"Drug-Induced senescent multiple myeloma cells elicit NK cell proliferation by direct or exosome-mediated IL15 trans-presentation","volume":"6","author":"Borrelli","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.18632\/oncotarget.1049","article-title":"Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma","volume":"4","author":"Xie","year":"2013","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van","year":"2009","journal-title":"Mol Cancer Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J Clin Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-07-4744","article-title":"Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma","volume":"14","author":"Armeanu","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol Immunother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fimmu.2016.00351","article-title":"Features of memory-like and PD-1+ human NK cell subsets","volume":"7","author":"Della","year":"2016","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"E516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/bjh.14263","article-title":"Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed\/refractory multiple myeloma","volume":"175","author":"Mateos","year":"2016","journal-title":"Br J Haematol."},{"key":"B52","volume-title":"Elotuzumab Plus Pomalidomide\/Dexamethasone (EPD) vs. PD for Treatment of Relapsed\/Refractory Multiple Myeloma (RRMM): Results from the Phase 2, Randomized Open-Label ELOQUENT-3 Study","author":"Dimopoulos","year":"2018"},{"key":"B53","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1034\/j.1399-0039.1999.540103.x","article-title":"Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4","volume":"54","author":"Boles","year":"1999","journal-title":"Tissue Antigens"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","article-title":"Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family","volume":"167","author":"Bouchon","year":"2001","journal-title":"J Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan","year":"2002","journal-title":"Mol Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1002\/eji.200424917","article-title":"Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs","volume":"34","author":"Lee","year":"2004","journal-title":"Eur J Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/intimm\/dxh358","article-title":"2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells","volume":"18","author":"Stark","year":"2006","journal-title":"Int Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"7996","DOI":"10.4049\/jimmunol.175.12.7996","article-title":"The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells","volume":"175","author":"Tassi","year":"2005","journal-title":"J Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e92184","DOI":"10.1371\/journal.pone.0092184","article-title":"Fine specificity and molecular competition in SLAM family receptor signalling","volume":"9","author":"Wilson","year":"2014","journal-title":"PLoS ONE"},{"key":"B64","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1600-065X.2009.00824.x","article-title":"Importance and mechanism of \u2018switch\u2019 function of SAP family adapters","volume":"232","author":"Veillette","year":"2009","journal-title":"Immunol Rev."},{"key":"B65","first-page":"2649","article-title":"EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS\/FLI1 fusion gene","volume":"13","author":"Thompson","year":"1996","journal-title":"Oncogene"},{"key":"B66","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1084\/jem.20132038","article-title":"EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase C\u03b3, Ca++, and Erk, leading to granule polarization","volume":"211","author":"Perez-Quintero","year":"2014","journal-title":"J Exp Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1128\/MCB.01107-14","article-title":"Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells","volume":"35","author":"Guo","year":"2015","journal-title":"Mol Cell Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.immuni.2015.02.013","article-title":"Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals","volume":"42","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","article-title":"Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function","volume":"42","author":"Schlums","year":"2015","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1042\/bj3610431","article-title":"A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion","volume":"361","author":"Murphy","year":"2002","journal-title":"Biochem J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1128\/IAI.00895-12","article-title":"Role of the NK cell-activating receptor CRACC in periodontitis","volume":"81","author":"Kramer","year":"2013","journal-title":"Infect Immun."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.4049\/jimmunol.179.7.4672","article-title":"CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes","volume":"179","author":"Lee","year":"2007","journal-title":"J Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e45466","DOI":"10.1371\/journal.pone.0045466","article-title":"High-resolution transcriptome of human macrophages","volume":"7","author":"Beyer","year":"2012","journal-title":"PLoS ONE"},{"key":"B74","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4049\/jimmunol.175.2.749","article-title":"Phospholipase C-gamma 2 is a critical signaling mediator for murine NK cell activating receptors","volume":"175","author":"Tassi","year":"2005","journal-title":"J Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1600-065X.2006.00453.x","article-title":"NK cell regulation by SLAM family receptors and SAP-related adapters","volume":"214","author":"Veillette","year":"2006","journal-title":"Immunol Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","article-title":"Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets","volume":"118","author":"Wong","year":"2011","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Ther."},{"key":"B78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.170.2.481","article-title":"Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils","volume":"170","author":"Ravetch","year":"1989","journal-title":"J Exp Med."},{"key":"B79","first-page":"218","article-title":"Receptors for the Fc fragment of IgG on natural killer cells","volume":"12","author":"Trinchieri","year":"1993","journal-title":"Nat Immun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1385\/IR:29:1-3:219","article-title":"Functional regulation of human neutrophil Fc gamma receptors","volume":"29","author":"Selvaraj","year":"2004","journal-title":"Immunol Res."},{"key":"B81","volume-title":"Elotuzumab Promotes Self-Engagement of SLAMF7 Between Natural Killer and Multiple Myeloma Cells to Enhance Cytotoxicity","author":"Pazina","year":"2018"},{"key":"B82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/278451a0","article-title":"The beige mutation in the mouse selectively impairs natural killer cell function","volume":"278","author":"Roder","year":"1979","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","article-title":"Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells","volume":"7","author":"Richards","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","article-title":"M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro","volume":"182","author":"Leidi","year":"2009","journal-title":"J Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/imr.12347","article-title":"bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression","volume":"268","author":"Gordan","year":"2015","journal-title":"Immunol Rev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"B87","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,4]],"date-time":"2018-11-04T23:32:05Z","timestamp":1541374325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2018.02551"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02551","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"article-number":"2551"}}